IBA reports strong mid-2025 results, transforming itself into a more profitable company Skip to main content

28.08.2025

IBA Dosimetry GmbH

IBA reports strong mid-2025 results, transforming itself into a more profitable company

Louvain-la-Neuve, Belgium, August 28, 2025 - IBA (Ion Beam Applications S.A), the world leader in particle gas pedal technology, today announces its consolidated results for the first half of 2025.


Strong sales growth and improved profitability in H1 thanks to accelerated backlog conversion

  • Net sales increased by 40% vs. H1 2024, to 304.9 million euros, with IBA Clinical and IBA Technologies up 47% and 30% respectively, thanks to a well-executed backlog conversion.
  • Gross margin decreased to 29.5% from 32.6% in H1 2024, due to a less favorable equipment/profitability mix (including low-margin legacy proton therapy projects), partially offset by productivity improvements.
  • Net operating profit of €10.6 million, compared with €0.0 million in H1 2024, with OPEX under control representing 26% of total net sales and IBA Clinical Net Operating Profit at break-even.
  • Net loss of €2.6 million reflecting targeted, non-recurring expenses such as migration to a new ERP system [1] and exchange rate fluctuations (mainly EUR/USD)

.....

Olivier Legrain, Chief Executive Officer of IBA, commented:"We are pleased to report a solid first half, marked by a well-executed backlog conversion and well-managed operating expenses, which contributed to improved financial performance.


As we reach this inflection point, the impact of our strategic initiatives is becoming increasingly evident. Our key growth drivers continue to develop, positioning us favorably for sustainable, profitable growth.


We remain committed to delivering ongoing value to our stakeholders, confident in our ability to build on this foundation of growth and resilience."


_______________

[1] Enterprise resource planning system, scheduled for completion in early 2026

[2] H1 2024 figures restated to reflect change in IFRS15 Agent vs. Principal treatment and new segmentation, announced when 2024 year-end results are published. For further information, please refer to the appendix.



Exhibitor Data Sheet
Return to top